ASTERO ERADO INC

College Station, TX · Biotech · Private

Engineered antibody-based therapeutics (Seldeg technology) that selectively deplete pathogenic FH-specific autoantibodies for autoimmune aHUS treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: College Station, TX
Total capital: $6.6M

Federal grants: $6.6M; 11 awards · 2021–2026; Rank in peer group#98 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

May 2026Federal grantHealth and Human S · Phase II · Novel approaches for the treatment of autoimmune disease$1M
Jun 2025Federal grantHealth and Human S · Phase II · Depleting autoantibodies for the treatment of autoimmunity$863K
Apr 2025Federal grantHealth and Human S · Phase II · Novel approaches for the treatment of autoimmune disease$1M
Jun 2024Federal grantHealth and Human S · Phase I · Novel treatments for Autoimmune Disease$293K
Mar 2024Federal grantHealth and Human S · Phase II · Depleting autoantibodies for the treatment of autoimmunity$1M
Jun 2023Federal grantHealth and Human S · Phase I · Novel treatments for Autoimmune Disease$305K
Mar 2023Federal grantHealth and Human S · Phase II · Depleting autoantibodies for the treatment of autoimmunity$1M

Show 4 earlier federal awards

Dec 2022Federal grantHealth and Human S · Phase I · Novel approaches for the treatment of autoimmune disease$275K
Mar 2022Federal grantHealth and Human S · Phase I · Depleting autoantibodies for the treatment of autoimmunity$252K
Aug 2021Federal grantHealth and Human S · Phase I · Autoantibody depletion for the therapy of autoimmune disease$246K
Jul 2021Federal grantHealth and Human S · Phase I · Targeting autoreactive antibodies for the therapy of MOG antibody-associated disease$251K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#98 · top 19%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

PROGENRA INCSimilar federal contract value in Biotech · null in contracts
ATGC Inc.Similar federal contract value in Biotech · null in contracts
VONA THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
CONIFER POINT PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · null in contracts
Turning Point TherapeuticsSimilar federal contract value in Biotech · null in contracts
Stylus MedicineSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.